More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators
A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences
They should set realistic expectations, monitor key metabolic markers, and reinforce lifestyle measures through multidisciplinary support
What are GLP-1 medications for weight loss
Studies using animal models of obesity have found typical neurobiological characteristics of addiction in the brain systems, which result from behaviors similar to addiction to fat and sugar-rich foods
NPs play a key role in addressing these barriers, advocating for patients, and promoting informed, stigma-free discussions that support safe and equitable use
